Baxter International Inc., through its subsidiaries, develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions worldwide. The company’s products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, clinical and medical research laboratories, and by patients at home under physician supervision. It manufactures products in 30 countries. Business Segments and Products The company operates in two segments, BioScience and Medical Products. BioScience This segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; biosurgery products; and select vaccines. The BioScience segment includes four commercial franchises, such as Hemophilia, BioTherapeutics, BioSurgery, and Vaccines. Hemophilia includes sales of recombinant factor VIII products and plasma-derived hemophilia products (primarily plasma-derived factor IX, factor VIII and inhibitor therapies). BioTherapeutics includes sales of the company’s antibody-replacement immunoglobulin therapies and other plasma-based therapies, such as albumin and alpha-1 antitrypsin products. BioSurgery consists of biological products and medical devices used in surgical procedures for hemostasis, tissue sealing, adhesion prevention and hard tissue repair, as well as soft tissue repair and microsurgery products. Vaccines consists primarily of vaccines for meningitis C and tick-borne encephalitis, as well as ongoing collaborations for the development of seasonal and pandemic influenza vaccines. Medical Products This segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics. The business also provides products and services related to pharmacy compounding, drug formulation and packaging technologies. In addition, the Medical Products business provides products and services to treat end-stage renal disease, or irreversible kidney failure, along with other renal therapies, which was enhanced in 2013 through the acquisition of Gambro AB (Gambro). The Medical Products business offers a comprehensive portfolio to meet the needs of patients across the treatment continuum, including technologies and therapies for peritoneal dialysis (PD), in-center hemodialysis (HD), home hemodialysis (HHD), continuous renal replacement therapy (CRRT) and additional dialysis services. The Medical Products segment includes four commercial franchises: Fluid Systems, Renal, Specialty Pharmaceuticals, and BioPharma Solutions. Fluid Systems principally includes IV therapies, infusion pumps, administration sets and premixed and oncology drug platforms. Renal consists of therapies for PD, HD, HHD and CRRT. Specialty Pharmaceuticals principally includes nutrition and anesthesia products. BioPharma Solutions principally includes sales from the pharmaceutical partnering business and pharmacy compounding services. Sales and Distribution The company has its own direct sales force and also makes sales to and through independent distributors, drug wholesalers acting as sales agents and specialty pharmacy or other alternate site providers. In the United States, third parties, such as Cardinal Health, Inc. and Owens & Minor, Inc. warehouse and ship a significant portion of the company’s products through their distribution centers. International Operations The company’s international presence includes operations in Europe (including Eastern and Central Europe), the Middle East, Africa, the Asia-Pacific, Latin America and Canada. Research and Development Expenditures for the company’s research and development activities were $1.25 billion in 2013. Government Regulation The Food and Drug Administration (FDA) in the United States, the European Medicines Agency in Europe, the State Food and Drug Administration in China, and other government agencies inside and outside of the United States, administer requirements covering the testing, safety, effectiveness, manufacturing, labeling, promotion and advertising, distribution and post-market surveillance of the company’s products. The company must obtain specific approval from FDA and non-U.S. regulatory authorities before it could market and sell majority of its products in a particular country. In the United States, the company is subject to the oversight of FDA, Office of the Inspector General within the Department of Health and Human Services, the Center for Medicare/Medicaid Services, the Department of Justice, Environmental Protection Agency, Department of Defense and Customs and Border Protection in addition to others. Significant Events In March 2014, Baxter International Inc. announced plans to create two separate, independent global healthcare companies - one focused on developing and marketing biopharmaceuticals and the other on life-saving medical products. In April 2014, Takeda and Baxter International Inc. entered into a development, license and technology transfer agreement in which Baxter licensed exclusive rights to its proprietary cell culture-based pandemic influenza vaccine technology for the Japanese market. Under this agreement, Takeda has been conducting pandemic influenza vaccine development activities jointly with Baxter. In August 2014, Baxter International Inc. announced the formal opening of its first advanced recombinant biologic facility in Singapore, and expansion plans for a new recombinant protein processing suite. History Baxter International Inc. was founded in 1931. The company was incorporated under Delaware law in 1931.
baxter international inc (BAX:New York)
One Baxter Parkway
Deerfield, IL 60015
|Astellas Pharma Inc||¥1,517 JPY||+21.00|
|Covidien PLC||$88.79 USD||+0.35|
|Danone SA||€52.99 EUR||-0.19|
|Kimberly-Clark Corp||$108.57 USD||+0.11|
|Takeda Pharmaceutical Co Ltd||¥4,718 JPY||+31.50|
|View Industry Companies|
Sponsored Financial Commentaries
To contact BAXTER INTERNATIONAL INC, please visit www.baxter.com. Company data is provided by Capital IQ. Please use this form to report any data issues.